Kymera Therapeutics, Inc.
KYMR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$110.76
KIRA · Stoqly’s AI analyst, in plain words
- Kymera Therapeutics, Inc. had $39.2M of revenue in fiscal 2025, down 16.7% on the year before. Over five years, revenue changed +2.9% a year on average.
- Its operating margin was −891.1%, down 335.3 pts: of every 100 in sales, about −891 is left after running the business.
- Kymera Therapeutics, Inc. lost $311M in fiscal 2025.
- Free cash flow was −$234M in fiscal 2025, −597.6% of revenue.
Market cap
$10.9B
P/E
—
Revenue
$39.2M
Net income
−$311M
Free cash flow
−$234M
Operating margin
−891.1%
Kymera Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−16.7%
No. Sales fell 16.7% last year.
Does it make a profit?
−794.0%
No. It lost money last year.
Does profit turn into cash?
−597.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kymera Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Kymera Therapeutics, Inc.
- CIK
- 0001815442
Kymera Therapeutics, Inc. · KYMR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Revenue growth | 114.0% | −35.7% | 67.8% | −40.1% | −16.7% |
| Gross margin | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating margin | −138.0% | −344.4% | −210.6% | −555.8% | −891.1% |
| Net income | −$100M | −$155M | −$147M | −$224M | −$311M |
| Net margin | −137.6% | −330.6% | −187.0% | −475.6% | −794.0% |
| Diluted EPS | −$2.09 | −$2.87 | −$2.52 | −$2.98 | −$3.69 |
| Cash | |||||
| Cash from operations | −$129M | −$153M | −$103M | −$195M | −$233M |
| Capital expenditure | $1.6M | $2.8M | $34.5M | $12.8M | $1.4M |
| Free cash flow | −$131M | −$156M | −$137M | −$207M | −$234M |
| FCF margin | −179.2% | −333.0% | −174.7% | −440.5% | −597.6% |
| Share count change | 176.6% | 12.4% | 8.2% | 28.6% | 12.6% |
| Debt and strength | |||||
| Cash and short-term investments | $442M | $407M | $375M | $489M | $848M |
| Shareholders' equity | $460M | $490M | $395M | $836M | $1.6B |
| Current ratio | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Returns and quality | |||||
| Return on equity | −27.0% | −32.6% | −33.2% | −36.4% | −25.8% |
| Return on tangible equity | −21.8% | −31.6% | −37.2% | −26.8% | −19.7% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 3 |
| Altman Z'' | 4.8 | 4.5 | 1.0 | 4.8 | 9.8 |
Insiders bought, 12 months
$172M
1 insider
Insiders sold, 12 months
$467M
11 insiders
Of sales under plans
57%
$268M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kymera Therapeutics, Inc. · KYMR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $110.76 a share, the company is worth $10.9B.
Source: SEC EDGAR XBRL filings (CIK 0001815442). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.